Clinical Trials Directory

Trials / Completed

CompletedNCT06148129

Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients

Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
96 (actual)
Sponsor
Zagazig University · Other Government
Sex
Female
Age
36 Years – 72 Years
Healthy volunteers
Not accepted

Summary

The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy \& Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment. Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTissue BiopsyThe Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM

Timeline

Start date
2019-01-12
Primary completion
2021-10-01
Completion
2022-03-01
First posted
2023-11-28
Last updated
2023-11-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06148129. Inclusion in this directory is not an endorsement.